| Systematic (IUPAC) name | |
|---|---|
| 1-pentyl-3-(2-iodobenzoyl)indole | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 335160-91-3 |
| ATC code | ? |
| ChemSpider | 25991468 |
| Chemical data | |
| Formula | C20H20INO |
| Mol. mass | 417.283 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
AM-679 is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5nM at CB1 and 49.5nM at CB2.[1] AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised cannabinoid ligands that are now widely used in research, including the potent CB1 agonists AM-694 and AM-2233, and the selective CB2 agonist AM-1241.[2] AM-679 was first identified as having been sold as a cannabinoid designer drug in Hungary in 2011, along with another novel compound 1-pentyl-3-(1-adamantoyl)indole.[3]
|
|||||||||||||||||||||||||||||||||||||||||||||||||
| This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)